News | Artificial Intelligence | August 10, 2023

AI Breakthrough Award Presented to Cleerly CCTA Digital Care Platform

Cleerly, an artificial intelligence (AI) digital healthcare company, has announced it was named “Best Overall AI Solution” in the sixth annual AI Breakthrough Awards program conducted by AI Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market.

Cleerly, an artificial intelligence (AI) digital healthcare company, recently announced it was named “Best Overall AI Solution” in the sixth annual AI Breakthrough Awards program conducted by AI Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market. Image courtesy: AI Breaktrhough.


August 10, 2023 — Cleerly, an artificial intelligence (AI) digital healthcare company, recently announced it was named “Best Overall AI Solution” in the sixth annual AI Breakthrough Awards program conducted by AI Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market.

Cleerly’s digital care platform helps physicians precisely identify, define, and treat heart disease at its earliest stages, when it is most treatable. The platform leverages non-invasive coronary computed tomography angiography (CCTA) to perform comprehensive coronary artery phenotyping through AI-powered and FDA-cleared solutions. This technology is based on millions of annotated lab images used to build more than two dozen proprietary algorithms capable of quantifying and characterizing the presence, extent, severity, and type of coronary artery disease (CAD) and other cardiovascular disorders.

Using Cleerly’s advanced machine learning and AI, providers can perform comprehensive assessments of a patient’s CCTA, studying each artery and branch. This assessment shows a patient’s risk of CAD and takes just seven minutes. The diagnostic tools and reporting solutions are tailored to all stakeholders in the heart care pathway, including patients, and the personalized reporting allows providers to deliver precision treatment. The company notes that through its FDA-cleared solutions driven by artificial intelligence, Cleerly helps enable comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging.

“I believe that a world without heart attacks is achievable in our lifetime. Using AI to drastically reduce the time it takes to identify health issues and ultimately identify every individual at risk of heart disease and prevent heart attacks before they occur is possible with our solution and the continuing refinement of it,” said James K. Min, MD, FACC, FESC, MSCCT, Founder and CEO of Cleerly. “We’re grateful AI Breakthrough recognizes the importance of our work as we strive to emulate the world’s most successful preventive care paradigms in medicine, which have historically been in early cancer detection,” added Min.

The mission of the AI Breakthrough Awards, now in its sixth year, is to honor excellence and recognize the innovation, hard work and success in a range of AI and machine learning related categories, including Generative AI, Computer Vision, AIOps, Deep Learning, Robotics, Natural Language Processing, industry specific AI applications and many more, according to the statement announcing the selection. This year’s program attracted more than 3,200 nominations from over 20 different countries throughout the world.

James Johnson, managing director, AI Breakthrough, said this of the distinction: “Cleerly’s breakthrough use of AI makes them our choice for the ‘Best Overall AI Solution.’ What sets them apart is their technology allows for whole-heart quantification and characterization of actual heart disease as opposed to surrogate or indirect markers of heart disease. By leveraging AI for advanced imaging, Cleerly is pioneering the transformation of heart disease by using this approach towards precision prevention and paving the way for a new future of cardiovascular care.”

Cleerly Inc. is headquartered in New York, NY, with locations in Denver, CO and Lisbon, Portugal.

More information: www.cleerlyhealth.com


Related Content

News | FDA

May 17, 2024 — Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has ...

Home May 17, 2024
Home
News | FDA

May 15, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling the HeartMate 3 LVAS by ...

Home May 15, 2024
Home
News | FDA

May 8, 2024 — The US Food and Drug Administration (FDA) is alerting health care providers and facilities about our ...

Home May 08, 2024
Home
News | FDA

May 8, 2024 — 4C Medical Technologies, Inc. ("4C Medical"), a medical device company dedicated to advancing minimally ...

Home May 08, 2024
Home
News | FDA

May 7, 2024 — RapidAI, the global leader in developing clinically deep Artificial Intelligence (AI) and technology ...

Home May 07, 2024
Home
News | FDA

April 25, 2024 — Provisio Medical announced FDA 510(k) clearance of the Provisio SLT IVUS System. Sonic Lumen Tomography ...

Home April 25, 2024
Home
News | FDA

April 24, 2024 — Expanse ICE announced today the ICE Aspiration System has received 510(k) clearance from the U.S. Food ...

Home April 24, 2024
Home
News | FDA

April 22, 2024 — At the annual American College of Cardiology conference (ACC.24) in Atlanta last week, RCE Technologies ...

Home April 22, 2024
Home
News | FDA

April 18, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently ...

Home April 18, 2024
Home
News | FDA

April 15, 2024 — The U.S. Food and Drug Administration (FDA) announced Abbott/Thoratec Corp. is recalling HeartMate II ...

Home April 15, 2024
Home
Subscribe Now